BACKGROUND AIMS: Immunotherapy targeting MAGE-A3 in multiple myeloma (MM) could eradicate highly aggressive and proliferative clonal cell populations responsible for relapse. However, expression of many cancer-testis antigens, including MAGE-A3, can be heterogeneous, leading to the potential for tumor escape despite MAGE-A3-induced immunity. We hypothesized that a combination of the hypomethylating agent 5-azacitidine (5AC) and the histone deacetylase inhibitor (HDACi) MGCD0103 (MGC) could induce MAGE-A3 expression in MAGE-A3-negative MM, resulting in recognition and killing of MM cells by MAGE-A3-specific cytotoxic T lymphocytes (CTL). METHODS: Gene expression analyses of MAGE-A3 expression in primary MM patient samples at diagnosis and relapse were completed to identify populations that would benefit from MAGE-A3 immunotherapy. MM cell lines were treated with 5AC and MGC. Real-time polymerase chain reaction (PCR) and Western blotting were performed to assess MAGE-A3 RNA and protein levels, respectively. Chromium-release assays and interferon (IFN) secretion assays were employed to ascertain MAGE-A3 CTL specificity against treated targets. RESULTS: Gene expression analysis revealed that MAGE-A3 is expressed in MM patients at diagnosis (25%) and at relapse (49%). We observed de novo expression of MAGE-A3 RNA and protein in MAGE-A3-negative cell lines treated with 5AC. MGC treatment alone did not induce expression but sequential 5AC/MGC treatment led to enhanced expression and augmented recognition by MAGE-A3-specific CTL, as assessed by (51)Cr-release assays (P = 0.047) and enzyme-linked immunosorbent assay (ELISA) for IFN-γ secretion (P = 0.004). CONCLUSIONS: MAGE-A3 is an attractive target for immunotherapy of MM and epigenetic modulation by 5AC, and MGC can induce MAGE-A3 expression and facilitate killing by MAGE-A3-specific CTL.
BACKGROUND AIMS: Immunotherapy targeting MAGE-A3 in multiple myeloma (MM) could eradicate highly aggressive and proliferative clonal cell populations responsible for relapse. However, expression of many cancer-testis antigens, including MAGE-A3, can be heterogeneous, leading to the potential for tumor escape despite MAGE-A3-induced immunity. We hypothesized that a combination of the hypomethylating agent 5-azacitidine (5AC) and the histone deacetylase inhibitor (HDACi) MGCD0103 (MGC) could induce MAGE-A3 expression in MAGE-A3-negative MM, resulting in recognition and killing of MM cells by MAGE-A3-specific cytotoxic T lymphocytes (CTL). METHODS: Gene expression analyses of MAGE-A3 expression in primary MM patient samples at diagnosis and relapse were completed to identify populations that would benefit from MAGE-A3 immunotherapy. MM cell lines were treated with 5AC and MGC. Real-time polymerase chain reaction (PCR) and Western blotting were performed to assess MAGE-A3 RNA and protein levels, respectively. Chromium-release assays and interferon (IFN) secretion assays were employed to ascertain MAGE-A3 CTL specificity against treated targets. RESULTS: Gene expression analysis revealed that MAGE-A3 is expressed in MM patients at diagnosis (25%) and at relapse (49%). We observed de novo expression of MAGE-A3 RNA and protein in MAGE-A3-negative cell lines treated with 5AC. MGC treatment alone did not induce expression but sequential 5AC/MGC treatment led to enhanced expression and augmented recognition by MAGE-A3-specific CTL, as assessed by (51)Cr-release assays (P = 0.047) and enzyme-linked immunosorbent assay (ELISA) for IFN-γ secretion (P = 0.004). CONCLUSIONS:MAGE-A3 is an attractive target for immunotherapy of MM and epigenetic modulation by 5AC, and MGC can induce MAGE-A3 expression and facilitate killing by MAGE-A3-specific CTL.
Authors: Fenghuang Zhan; Johanna Hardin; Bob Kordsmeier; Klaus Bumm; Mingzhong Zheng; Erming Tian; Ralph Sanderson; Yang Yang; Carla Wilson; Maurizio Zangari; Elias Anaissie; Christopher Morris; Firas Muwalla; Frits van Rhee; Athanasios Fassas; John Crowley; Guido Tricot; Bart Barlogie; John Shaughnessy Journal: Blood Date: 2002-03-01 Impact factor: 22.113
Authors: A A Jungbluth; Y T Chen; E Stockert; K J Busam; D Kolb; K Iversen; K Coplan; B Williamson; N Altorki; L J Old Journal: Int J Cancer Date: 2001-06-15 Impact factor: 7.396
Authors: A Serrano; S Tanzarella; I Lionello; R Mendez; C Traversari; F Ruiz-Cabello; F Garrido Journal: Int J Cancer Date: 2001-10-15 Impact factor: 7.396
Authors: C Pellat-Deceunynck; M P Mellerin; N Labarrière; G Jego; A Moreau-Aubry; J L Harousseau; F Jotereau; R Bataille Journal: Eur J Immunol Date: 2000-03 Impact factor: 5.532
Authors: N R dos Santos; R Torensma; T J de Vries; M W Schreurs; D R de Bruijn; E Kater-Baats; D J Ruiter; G J Adema; G N van Muijen; A G van Kessel Journal: Cancer Res Date: 2000-03-15 Impact factor: 12.701
Authors: Peter Kufer; Alfred Zippelius; Ralf Lutterbüse; Ingo Mecklenburg; Thomas Enzmann; Anthony Montag; Dorothea Weckermann; Bernward Passlick; Nadja Prang; Peter Reichardt; Martin Dugas; Manfred W Köllermann; Klaus Pantel; Gert Riethmüller Journal: Cancer Res Date: 2002-01-01 Impact factor: 12.701
Authors: A A Jungbluth; K J Busam; D Kolb; K Iversen; K Coplan; Y T Chen; G C Spagnoli; L J Old Journal: Int J Cancer Date: 2000-02-15 Impact factor: 7.396
Authors: Djordje Atanackovic; York Hildebrandt; Adam Jadczak; Yanran Cao; Tim Luetkens; Sabrina Meyer; Sebastian Kobold; Katrin Bartels; Caroline Pabst; Nesrine Lajmi; Maja Gordic; Tanja Stahl; Axel R Zander; Carsten Bokemeyer; Nicolaus Kröger Journal: Haematologica Date: 2009-12-16 Impact factor: 9.941
Authors: A A Jungbluth; E Stockert; Y T Chen; D Kolb; K Iversen; K Coplan; B Williamson; N Altorki; K J Busam; L J Old Journal: Br J Cancer Date: 2000-08 Impact factor: 7.640
Authors: Amir A Toor; Kyle K Payne; Harold M Chung; Roy T Sabo; Allison F Hazlett; Maciej Kmieciak; Kimberly Sanford; David C Williams; William B Clark; Catherine H Roberts; John M McCarty; Masoud H Manjili Journal: Br J Haematol Date: 2012-07-23 Impact factor: 6.998
Authors: Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard Journal: Clin Cancer Res Date: 2011-09-09 Impact factor: 12.531
Authors: Aksinija A Kogan; Michael J Topper; Anna J Dellomo; Lora Stojanovic; Lena J McLaughlin; T Michael Creed; Christian L Eberly; Tami J Kingsbury; Maria R Baer; Michael D Kessler; Stephen B Baylin; Feyruz V Rassool Journal: Proc Natl Acad Sci U S A Date: 2022-06-27 Impact factor: 12.779
Authors: Michael J Topper; Michelle Vaz; Katherine B Chiappinelli; Christina E DeStefano Shields; Noushin Niknafs; Ray-Whay Chiu Yen; Alyssa Wenzel; Jessica Hicks; Matthew Ballew; Meredith Stone; Phuoc T Tran; Cynthia A Zahnow; Matthew D Hellmann; Valsamo Anagnostou; Pamela L Strissel; Reiner Strick; Victor E Velculescu; Stephen B Baylin Journal: Cell Date: 2017-11-30 Impact factor: 41.582
Authors: Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin Journal: Nat Rev Clin Oncol Date: 2019-09-23 Impact factor: 66.675
Authors: Ken Maes; Eline Menu; Els Van Valckenborgh; Ivan Van Riet; Karin Vanderkerken; Elke De Bruyne Journal: Cancers (Basel) Date: 2013-04-15 Impact factor: 6.639